Kepler Capital downgrades Amplifon S.p.A. (0N61) to a Hold
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Guido Storer covers the Consumer Cyclical sector, focusing on stocks such as Ferretti S.p.A., EssilorLuxottica SA, and De'Longhi S.p.A.. According to TipRanks, Guido Storer has an average return of 14.2% and a 50.94% success rate on recommended stocks.
In addition to Kepler Capital , Amplifon S.p.A. also received a Hold from Bank of America Securities's Julien Ouaddour in a report issued on July 31. However, yesterday, Morgan Stanley maintained a Buy rating on Amplifon S.p.A. (LSE: 0N61).
Based on Amplifon S.p.A.'s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of €587.79 million and a net profit of €32.89 million. In comparison, last year the company earned a revenue of €573.11 million and had a net profit of €34.86 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Is WH Smith PLC (LON:SMWH) Potentially Undervalued?
WH Smith PLC (LON:SMWH), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in the past couple of months on the LSE. While good news for shareholders, the company has traded much higher in the past year. As a stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. But what if there is still an opportunity to buy? Let's take a look at WH Smith's outlook and value based on the most recent financial data to see if the opportunity still exists. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Is WH Smith Still Cheap? The stock is currently trading at UK£10.33 on the share market, which means it is overvalued by 20% compared to our intrinsic value of £8.60. This means that the opportunity to buy WH Smith at a good price has disappeared! But, is there another opportunity to buy low in the future? Given that WH Smith's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility. See our latest analysis for WH Smith Can we expect growth from WH Smith? Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to more than double over the next couple of years, the future seems bright for WH Smith. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation. What This Means For You Are you a shareholder? SMWH's optimistic future growth appears to have been factored into the current share price, with shares trading above its fair value. However, this brings up another question – is now the right time to sell? If you believe SMWH should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed. Are you a potential investor? If you've been keeping tabs on SMWH for some time, now may not be the best time to enter into the stock. The price has surpassed its true value, which means there's no upside from mispricing. However, the positive outlook is encouraging for SMWH, which means it's worth diving deeper into other factors in order to take advantage of the next price drop. So while earnings quality is important, it's equally important to consider the risks facing WH Smith at this point in time. Every company has risks, and we've spotted 4 warning signs for WH Smith you should know about. If you are no longer interested in WH Smith, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
40 minutes ago
- Yahoo
How many Lloyds shares do investors need to buy to earn a £1,000 monthly passive income today?
Lloyds (LSE:LLOY) shares are among some of the most popular investments among UK investors. And it's not entirely hard to understand why. After all, the banking giant serves a mission-critical role within the UK economy that gives it several desirable defensive traits. And pairing that with a tasty-looking 4.2% dividend yield, snapping up some shares could be a terrific way to unlock a reliable and consistent passive income. So let's say an investor wants to earn £1,000 a month from Lloyds dividends. How many shares do they need to buy? And is it actually a good idea? Crunching the numbers In 2024, Lloyds paid out 3.17p per share in dividends. But if the analyst forecasts are correct, that could jump to 3.49p by the end of 2025 – something that's looking increasingly likely given the interim payment enjoyed a similar 15% boost. If the goal is £1,000 a month, or £12,000 a year, at 3.49p, an investor will need to buy 343,840 shares. And at today's stock price, such an investment would cost around £269,000. Obviously, that's not pocket change. But by drip-feeding money in over time and reinvesting any dividends received along the way, investors could eventually build such a position and go on to enjoy an extra grand each month. Is Lloyds a good investment? Before setting off on the quest to buy almost 350,000 Lloyds shares, it's essential to analyse both the risks and potential rewards. On the bull side of the argument, there's a lot to like about this business. The higher interest rate environment has helped bolster lending margins. In turn, the balance sheet's now flooded with liquid assets that comfortably exceed regulatory requirements. And while interest rates are steadily being cut, the impact is being offset by higher lending volumes, especially when it comes to mortgages. That's good news for cash flows and, in turn, dividends. But like every investment, there are key risks to consider, the most prominent of which is regulatory and legal uncertainty. Changes in banking rules and the discovery of financial scandals – something the banking industry is notorious for – can have a massive impact on the business. An increase in regulatory capital provisions, or issued legal penalties, could gobble up free cash flow, potentially disrupting dividends as well as the Lloyds share price. At the same time, an economic slowdown in a lower interest rate environment may also hamper borrowing activity from customers. And with fewer loans being issued, there's less cash flow to offset the compression of Lloyds' net interest income. The bottom line All things considered, Lloyds shares appear to offer an appealing dividend backed by a robust financial position. But the business is also weighed down by UK macroeconomic and regulatory uncertainty that could prevent the stock from living up to expectations. Investors who are comfortable taking on these long-term persistent risks, the stock could be worthy of closer inspection. But personally, I think there are other more attractive passive income opportunities than investing in Lloyds shares. The post How many Lloyds shares do investors need to buy to earn a £1,000 monthly passive income today? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended Lloyds Banking Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
5 hours ago
- Business Insider
Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here's What to Expect
Hims & Hers Health (HIMS) is scheduled to announce its results for the second quarter of 2025 after the market closes on Monday, August 4. HIMS stock has rallied 171% year-to-date, as investors are confident about the prospects of the health and wellness company, including its continued international expansion. However, Wall Street is cautious on Hims & Hers Health stock due to certain concerns, including the recent fallout with Novo Nordisk (NVO) over the alleged illegal sale of compounded versions of the weight loss drug Wegovy. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Wall Street expects HIMS to report earnings per share (EPS) of $0.15, reflecting a 150% year-over-year growth. Sales are expected to grow by about 75% to $551.67 million. TD Cowen Analyst's Views Ahead of Hims & Hers Health's Q2 Earnings Heading into Q2 results, TD Cowen analyst Jonna Kim reiterated a Hold rating on HIMS stock but raised the price target to $43 from $38. The 4-star analyst expects the company to deliver an EPS beat. Kim expects Q2 sales growth to come above the Street's estimate. However, Kim noted that the latest data points indicate a deceleration in trends, which could lead to management maintaining the full-year outlook. The analyst remains neutral on HIMS stock as comparisons get tougher in the second half of 2025, with uncertainty around compounded GLP-1s. Nonetheless, Kim believes that international growth could be meaningful to HIMS' sales starting in Fiscal 2026. Kim noted the rally in HIMS stock and stated that he sees a lack of substantial upside in the second half of 2025, as the company 'laps outsized growth' from last year. AI Analyst Is Bullish on HIMS Stock Ahead of Q2 Print Interestingly, TipRanks' AI stock analyst has assigned an Outperform rating to HIMS stock with a price target of $73, indicating 16.7% downside risk. Based on TipRanks' AI analysis, HIMS stock reflects significant strength in financial performance and strategic growth plans, supported by favorable earnings call insights. However, high valuation and technical indicators suggest caution, especially given potential overbought conditions and margin pressures. Options Traders Anticipate Major Move on Hims & Hers Health's Q2 Earnings Using TipRanks' Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement. If this sounds complicated, don't worry, the Options tool does this for you. Indeed, it currently says that options traders are expecting about a 17.3% move in either direction in HIMS stock in reaction to Q2 results. Is HIMS Stock a Good Buy? Currently, Wall Street has a Hold consensus rating on Hims & Hers Health stock based on one Buy, seven Holds, and two Sell recommendations. The average HIMS stock price target of $42.33 indicates 32.3% downside risk from current levels.
